MUC1 and neoplasm: These results culminated in the establishment of a Phase IIb/III clinical trial, TIME, initiated in 2012 to primarily assess the efficacy of TG4010 plus first-line chemotherapy among a larger cohort of advanced NSCLC patients with an activating EGFR mutation and >50% of tumor cells expressing MUC1 [147,148].